Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

@article{Falutz2010EffectsOT,
  title={Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.},
  author={Julian M Falutz and Diane Potvin and Jean-Claude Mamputu and Hani Assaad and Monika Zoltowska and Sophie-Elise Michaud and Daniel Berger and Michael S Somero and Graeme Moyle and Stephen Scott Brown and Claudia T Martorell and Ralph O Turner and Steven Grinspoon},
  journal={Journal of acquired immune deficiency syndromes},
  year={2010},
  volume={53 3},
  pages={311-22}
}
BACKGROUND HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in this population. We investigated the effects of tesamorelin (GHRH(1-44)) in HIV-infected patients with central fat accumulation. METHODS A 12-month study of 404 HIV-infected patients with excess abdominal fat in the context of antiretroviral therapy was conducted between January 2007 and October 2008… CONTINUE READING
22 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Progression of subclinical atherosclerosis in HIV-infected patients

  • G Guaraldi, S Zona, G Orlando
  • Antivir Ther. 2009;14(Suppl 2):A11
  • 2009

Subcutaneous abdominal adipose tissue : a protective fat depot ?

  • SA Porter, JM Massaro, U Hoffman
  • Diabetes Care
  • 2009

Subcutaneous abdominal adipose tissue: a protective fat depot? Diabetes Care

  • SA Porter, JM Massaro, U Hoffman
  • 2009

Similar Papers

Loading similar papers…